- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
AMA to issue new code for conjunctivitis test
Rapid Pathogen Screening Inc. (RPS) has announced that the American Medical Association (AMA) will issue a new CPT code, 87809, for "Infectious agent antigen detection by immunoassay with direct optical observation; Adenovirus" to cover the company's proprietary test (Adeno Detector) effective Jan. 1.
Sarasota, FL-Rapid Pathogen Screening Inc. (RPS), a developer of point-of-care diagnostic devices for ocular diseases, has announced that the American Medical Association (AMA) will issue a new CPT code, 87809, for "Infectious agent antigen detection by immunoassay with direct optical observation; Adenovirus" to cover the company's proprietary test (Adeno Detector) effective Jan. 1.
The point-of-care test has been cleared by the FDA and waiver under the Clinical Laboratory Improvement Amendments of 1988. According to the company, it provides a definitive result in 10 minutes.
"The creation of a new CPT code reflects the value that the [test] provides to the patient, the clinician, and the health-care system at large," said Robert Sambursky, MD, chief medical officer, RPS. "With the CPT code, clinicians may use the [test] to diagnose and treat cases of acute conjunctivitis accurately. This not only will result in better patient care; it also will save millions in health-care dollars."
